Logo
x

Search

Subscribe Now

HR

Novartis Reports Results of Kisqali in Second Phase P-III MONALEESA-3 Study for HR+/HER2- Advanced Breast Cancer in Women

Novartis Reports Results of Kisqali in Second Phase P-III MONALEESA-3 Study for HR+/HER2- Advanced Breast Cancer in Women

  • August 1, 2019
Eli Lilly Reports Results of Verzenio (abemaciclib) in P-III MONARCH 2 for HR+ and HER2- Advanced Breast Cancer

Eli Lilly Reports Results of Verzenio (abemaciclib) in P-III MONARCH 2 for HR+ and HER2- Advanced Breast Cancer

  • July 30, 2019
Knight Therapeutics' Nerlynx (neratinib) Receives Health Canada Approval as Extended Adjuvant Therapy for HR+ and HER2+ Breast Cancer

Knight Therapeutics' Nerlynx (neratinib) Receives Health Canada Approval as Extended Adjuvant Therapy for HR+ and HER2+ Breast Can...

  • July 17, 2019
Novartis' Piqray (alpelisib) + Fulvestrant Receive FDA's Approval for Patients with a PIK3CA Mutation in HR+/HER2- Advanced/Metastatic Breast Cancer

Novartis' Piqray (alpelisib) + Fulvestrant Receive FDA's Approval for Patients with a PIK3CA Mutation in HR+/HER2- Advanced/Metast...

  • May 27, 2019
Novartis' Kisqali + Aromatase Inhibitor Receive FDA's Breakthrough Therapy Designation for HR+/HER2- Advanced Breast Cancer

Novartis' Kisqali + Aromatase Inhibitor Receive FDA's Breakthrough Therapy Designation for HR+/HER2- Advanced Breast Cancer

  • January 3, 2018
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.